As the OV-αCD47-G1 therapeutic combines OV-Q1 and αCD47-G1 into a single agent, and the single agent shows therapeutic survival outcomes superior to αCD47-G1 alone, OV-Q1 alone, and their combination, the two-in-one single agent, i.e., an oncolytic virus expressing a full-length IgG1 anti-CD47 antibody is an innovative, convenient, and effective approach for the treatment of experimental GBM. The gene discussed is CD47; the disease is glioblastoma.